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About 25% of all strokes occur during sleep, i.e., without knowledge of exact time of
symptom onset. According to licensing criteria, this large group of patients is excluded
from treatment with received tissue-plasminogen activator, the only specific stroke treat-
ment proven effective in large randomized trials. This paper reviews clinical and imaging
characteristics of wake-up stroke and gives an update on treatment options for these
patients. From clinical and imaging studies, there is evidence suggesting that many wake-
up strokes occur close to awakening and thus, patients might be within the approved
time-window of thrombolysis when presenting to the emergency department. Several
imaging approaches are suggested to identify wake-up stroke patients likely to benefit
from thrombolysis, including non-contrast CT, CT-perfusion, penumbral MRI, and the recent
concept of diffusion weighted imaging-fluid attenuated inversion recovery (DWI-FLAIR). A
number of small case series and observational studies report results of thrombolysis in
wake-up stroke, and no safety concerns have occurred, while conclusions on efficacy can-
not be drawn from these studies. To this end, there are ongoing clinical trials enrolling
wake-up stroke patients based on imaging findings, i.e., the DWI-FLAIR-mismatch (WAKE-
UP) or penumbral imaging (EXTEND). The results of these trials will provide evidence to
guide thrombolysis in wake-up stroke and thus, expand treatment options for this large
group of stroke patients.
Keywords: wake-up stroke, acute ischemic stroke, thrombolysis, computed tomography, magnetic resonance
imaging, fluid attenuated reversion recovery, DWI-FLAIR-mismatch
METHODS
The literature used in this review was searched in PUBMED and
MEDLINE (1977–2013 October) using the following key words
“wake-up stroke,” “stroke on awakening,” “stroke of unknown
symptom onset,” “thrombolysis,” “diffusion weighted imaging,”
and “fluid attenuated inversion recovery (FLAIR).” The selection
was made by the authors evaluating clinical relevance, currentness,
and methodical correctness. Our purpose was not to give a general
overview of the current state of literature concerning thromboly-
sis in wake-up stroke in general, but to emphasize the possibilities
of treatment for wake-up stroke on the basis of current literature.
Therefore, we have done no systematic literature review but one
focused on our demand.
STROKE AND STROKE THROMBOLYSIS
Patients waking-up with symptoms of stroke represent a specific
subgroup of stroke patients. In general, stroke is the second most
common single cause of death and the most frequent cause of
permanent disability in industrialized countries. Based on WHO
estimates about 15 million people suffer from stroke each year of
whom five million are left permanently disabled (1). As a conse-
quence, stroke carries an enormous social and economic burden
both for the individual patients as for society at large. In the EU
stroke accounts for just over 500,000 deaths each year with just
around 1 in 10 men (9%) and 1 in 8 women (12%) dying from
stroke (2).
The demonstration of efficacy and safety of treatment with
intravenous tissue plasminogen activator (IV-tPA) (3) has ended
an age of therapeutic nihilism and revolutionized stroke care.
Together with the establishment of the stroke-unit concept, throm-
bolysis has motivated the implementation of specialized acute
stroke treatment in most developed countries.
In ischemic stroke, the acute occlusion of a brain vessel leads
to hypoperfusion of the downstream brain areas resulting in an
insufficient supply with oxygen. Within seconds the functional
metabolism of brain cells breaks down, and depending on the
degree and duration of ischemia, the affected brain areas decay.
Thrombolysis aims to reperfuse the brain vessel occlusion by dis-
solution of the clot. In acute stroke, thrombolysis was proven
effective in two randomized controlled trials resulting in a marked
increase of the number of patients with a favorable outcome after
stroke (3, 4). In large observational trials, this effect was repro-
duced in the clinical practice (5), and thrombolysis has become
a keystone of acute stroke treatment. However, thrombolysis was
only proven effective in patients treated within 4.5 h of symptom
onset, and is only recommended for patients to be treated within
this time-window.
WAKE-UP STROKE
In a large number of stroke patients, the time point of symp-
tom onset is not known. About 20–25% of stroke patients realize
stroke symptoms after waking-up from sleep (6–9) (Table 1).
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This subgroup of stroke patients (“wake-up strokes”) differs from
stroke patients who suffer from stroke while being awake and pose
a specific challenge to stroke physicians. The most relevant dif-
ference between both groups is the fact that in wake-up stroke
patients, the exact time point of symptom onset is unknown. As a
result, according to approval criteria and guideline recommenda-
tions, this large group of patients is excluded from thrombolysis
(9, 10), thus excluding patients from the only approved specific
treatment of acute stroke with proven safety and efficacy.
Within the past years, however, wake-up stroke has come into
focus of research activities. Observational studies have brought
insights into clinical and imaging characteristics of wake-up
stroke; new approaches to guide treatment in wake-up stroke
patients have been suggested. Finally, clinical trials are under-
way testing intravenous thrombolysis in patients with unknown
time of symptom onset including wake-up stroke. We will give
an update of the recent insights on wake-up stroke and ongoing
developments that are likely to improve the treatment of these
patients in the near future.
CLINICAL AND IMAGING CHARACTERISTICS OF WAKE-UP
STROKE
There are observations that point toward strokes during sleep
being more severe (15) and having a worse clinical outcome
(12). In a recent large analysis of wake-up-stroke as compared
to stroke while awake, a smaller initial severity for wake-up-stroke
with deterioration to comparable mortality and morbidity was
shown (14). Especially, the secondary deterioration underlines
the potential responsiveness of wake-up stroke for therapy. In
addition, further clinical and imaging observations suggest that
in a large number of patients waking-up with stroke symptoms
strokes may have occurred in the early morning hours so that they
might still be eligible for thrombolysis. There are studies report-
ing comparable frequency of early ischemic signs on CT (EICs)
in wake-up stroke patients as compared to patients studied by CT
within 3 (16) or 6 h of symptom recognition (17). Additionally,
the equal developmental time pattern of EICs in patients with
known and unknown onset in a follow-up from 3 h after recog-
nizing the symptoms to 3 months supports the presumption that
wake-up strokes occur close to awakening (18). An MRI-based
study reported a similar proportion of wake-up stroke patients
showing a perfusion–diffusion-mismatch as compared to patients
within 3 h of symptom onset (11). A similar observation was made
for the detection of “tissue at risk” by perfusion CT in wake-up
stroke patients (18). Together these findings suggest that a large
number of patients with wake-up stroke might still be within a
time-window for thrombolysis when reaching the hospital.
IMAGING APPROACHES TO GUIDE TREATMENT IN WAKE-UP
STROKE
To identify wake-up stroke patients who may benefit from throm-
bolysis two imaging approaches are set in the focus of investi-
gation. The detection of tissue at risk by penumbral imaging
(perfusion–diffusion mismatch, Figure 1), and the approach of
identifying stroke patients within the 4.5 h-time-window by tis-
sue characteristics in stroke MRI [diffusion weighted imaging
(DWI)-FLAIR-mismatch]. Penumbral imaging based on DWI and
Table 1 | Incidence of wake-up stroke.
Wake-up strokes (%) Total Reference
100 (27) 364 (11)
301 (24) 1.248 (8)
349 (14) 2.585 (12)
48 (18) 263 (13)
273 (14)a (+12% “no estimation of onset”) 1.854 (6)
5.152 (30) 17.398 (14)
aOf note, according to clinical in- and exclusion criteria 36% of these patients
were potentially eligible for thrombolysis according to the authors.
FIGURE 1 | MRI perfusion–diffusion mismatch. The small lesion on
diffusion weighted imaging (DWI) represents the infarct core, while the
much larger area in the time to peak map calculated from perfusion imaging
(PWI) identifies the area of critically hypoperfused tissued. The mismatch
between both volumes represents the tissue at risk of infraction and thus,
the target tissue for reperfusion treatment.
perfusion MRI allows to determine the status of damaged tis-
sue in acute ischemia and to distinguish irreversibly damaged
one from critically hypoperfused but potentially salvageable tis-
sue. The mismatch of these was suggested to identify tissue that
is tPA-responsive beyond time-window or independent from time
(19–21). In observational studies, it was shown that tissue at risk
may be saved by reperfusion up to 6 h after symptom onset (22).
Secondary analysis of randomized controlled trials with selec-
tion by penumbral imaging (23, 24) demonstrated a reduction of
final infarct volume (25) and a clinical benefit of thrombolysis in
patients with a large perfusion–diffusion mismatch with an odds
ratio for good clinical response of 2.83 between desmoteplase and
placebo (26). Moreover, large DWI lesion volumes were found to
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be associated with a higher risk of symptomatic intracranial hem-
orrhage (SICH) and poor outcome (22, 27, 28). Thus, the exclusion
of patients with very large DWI lesion volumes by MRI will likely
increase the safety of MRI-based thrombolysis. The re-analysis of
EPITHET and DEFUSE resulted in a more restrictive definition
of the perfusion lesion (29, 30), which are used in the ongoing
Extending the time for Thrombolysis in Emergency Neurological
Deficits (EXTEND) trial (31). The detection of treatable wake-up
strokes by perfusion–diffusion mismatch has been suggested (32–
34) and used in a relatively small non-randomized trial (35). In
line with these considerations, the EXTEND trial will allow the
randomization of patients with wake-up stroke based penumbral
imaging.
The DWI-FLAIR-mismatch (Figure 2) concept refers to the
time-window. There is a broad and striking evidence for the ben-
efit of intravenous thrombolysis of ischemic stroke within 4.5 h
(3, 4, 35). Therefore, it was suggested to use brain imaging to
determine stroke age in the case of unknown symptom onset. The
chronological evolution of ischemic stroke can be characterized
by MRI. A lack of cerebral blood flow with a decreased intracel-
lular energy metabolism causes cytotoxic edema, which can be
detected by a reduced apparent diffusion coefficient (ADC) on
DWI within minutes of stroke (36, 37). During the following 1–4 h,
tissue osmolality increases, accompanied by a net increase of water
(38, 39). This absolute increase of water content can be detected by
T2-weighted MRI (36, 40). Thus, DWI allows an instant determi-
nation of acute ischemic lesions, but gives no evidence of further
developmental changes, which may be characterized by T2. Due
to artificial limitations of T2 caused by the high signal intensity of
cerebrospinal fluid (CSF) with partial volume effects FLAIR is con-
sidered superior and more widely used (41, 42). The pattern of a
visible ischemic lesion on DWI together with normal T2-weighted
imaging or FLAIR is a typical finding in human stroke if imaging is
performed within the first hours of stroke (43–45). These results
are also well in line with data from experimental stroke, where
T2wI failed to detect acute ischemia until about 2–3 h of stroke
(37, 46, 47).
The DWI/FLAIR-mismatch was established (48) to estimate
lesion age and identify patients likely to benefit from thrombol-
ysis. It differs from the perfusion–diffusion coefficient by reveal-
ing information about the time and not the quality of damage.
Single-center studies reported of a 100% visibility of ischemic
lesions after 3–6 h (49–51), and the DWI-FLAIR-mismatch was
shown to identify patients within 3–4.5 h with high specificity
and positive predicted value (PPV) (48–51). These results have
been confirmed in large multicenter studies (PRE-FLAIR: PRE-
dictive value of FLAIR and DWI for the identification of acute
ischemic stroke patients ≤3 and ≤4.5 h of symptom onset – a
multicenter study including 643 patients) (52). The specificity of
the DWI-FLAIR-mismatch to identify patients within the time
frame of 4.5 h was in this study 0.81 and the PPV 0.87. The iden-
tification within 6 h showed a PPV of 0.95 in PRE-FLAIR (50),
and 1 of 0.97 in a Japanese study (49). Concerning the Cochrane
analysis indicating a possible beneficial effect of thrombolysis in
addition with the absence of an increased risk of SICH up to
6 h of symptom onset (53, 54), these results are of paramount
interest for treatment indication. Just recently, an observational
study reported of a high frequency (44%) of wake-up strokes
FIGURE 2 | DWI-FLAIR-mismatch. The upper row gives two examples of a
clearly visible acute ischemic lesion on diffusion weighted imaging (DWI),
while no marked parenchymal hyperintensity is detected on fluid attenuated
inversion recovery (FLAIR) images indicating DWI-FLAIR-mismatch. In the
lower row, a clear hyperintensity can be seen on FLAIR images in the area of
the acute DWI lesion (no DWI-FLAIR-mismatch).
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showing a DWI-FLAIR-mismatch (55). Based on this evidence,
the Efficacy and safety of MRI-based thrombolysis in wake-up stroke:
a randomized, double-blind, placebo-controlled trial (WAKE-UP)
will randomize wake-up stroke patients using the DWI-FLAIR-
mismatch as the imaging criterion to identify patients likely to
benefit from thrombolysis (56).
THROMBOLYSIS IN WAKE-UP STROKE: CASE REPORTS AND
OBSERVATIONAL STUDIES
Resulting from the dissatisfaction with the lack of any evidence-
based treatment recommendations for patients with wake-up
stroke, there is a growing number of case reports and case series,
which report on thrombolysis in patients with wake-up stroke
based on imaging findings (Table 2). These studies used either
plain CT (50), multiparameteric CT (57–60), or multiparamet-
ric stroke MRI (32–35). In a study including 74 patients with
an onset time over 4.5 h and 73 patients with an unknown
onset no difference in eligibility and response for perfusion CT
based thrombolysis was shown (59). Non-contrast CT and clini-
cally indicated thrombolysis for wake-up ischemic stroke in over
80 years old patients was considered to be beneficial concern-
ing the modified Ranking Scale (mRS) after 90 days compared
to non-thrombolysed patients (61), and a comparison with ini-
tial and follow-up examination (mRS) after 90 days of 68 patients
with wake-up ischemic stroke to 326 patients within the time-
window of 4.5 h showed equal results after thrombolysis indicated
by non-contrast CT scan combined with clinical judgment (62).
In a further single-center observational safety study 20 patients
were treated with intravenous thrombolysis in the presence of an
arterial occlusion on CT-A and an ASPECTS score of greater than
five on baseline CT (60).
RESTORE (reperfusion therapy in unclear-onset stroke based
on MRI evaluation) was an observational study in which 83 of
430 patients with an unclear onset of symptoms received tissue-
plasminogen activator (rt-PA), intravenously, intra-arterial, or in
combination. The decision for applying this therapy was made
upon a perfusion–diffusion mismatch of more than 20% and neg-
ative or subtle hyperintensities on FLAIR. The clinical outcome
determined by the mRS after 3 months was in 44.6% favorable and
in 28.9% excellent compared to untreated patients (35). Intracra-
nial hemorrhage with a neurological decline was reported in 6% of
the treated patents. Therefore, a distinct benefit for patients being
treated with rt-PA due to estimation by MRI could be shown.
Restraints of this study are the non-randomized study design, the
non-quantitative measurement of FLAIR, and the relatively small
number of treated patients with unknown symptom onset.
Finally, there is a single-armed observational US American
study of thrombolysis with Alteplase in patients with unknown
symptom onset (MR WITNESS: a Study of Intravenous Throm-
bolysis with Alteplase in MRI-Selected Patients, ClinicalTrials.gov.
Identifier: NCT01282242). MR WITNESS will use the concept of
DWI-FLAIR-mismatch to identify patients likely to respond to
thrombolysis and plans to enroll 80 patients.
In summary, these studies demonstrate the feasibility of imag-
ing guided thrombolysis in wake-up stroke patients while there
was no excess in SICH and outcome appeared in large parts simi-
lar as compared to thrombolysis in patients treated within 4.5 h of
known symptom onset. However, final conclusions to the safety
Table 2 |Trials with thrombolysis with indication set by imaging in wake-up strokes.
Sample size wake-up stroke Imaging method Main results Reference
68 Strokes with unknown onset, all received
IV-tPA (case–control comparison)
NECT Similar outcome as treatment within 4.5 h (mRS
after 3 months, any ICH, symptomatic ICH)
(61, 62)
73 Strokes with unknown onset, in 32 (44%) of
these IV-tPA
Perfusion CT No SICH, 56% good outcome after 3 months
(mRS <2)
(59)
89 Strokes with unknown onset, in 20 (22%) of
these thrombolysis
NECT and CT-A/TCD Two asymptomatic ICH, none symptomatic, two
died of massive infarction, two died of stroke
complications
(60)
80 Wake-up strokes, 46 received thrombolysis
(intra-arterial, IV-tPA, or combined)
NCCT, CT- or
MRI-perfusion–diffusion mismatch
Two symptomatic ICH, better clinical outcome
(mRS) and higher mortality in treated cohort
(57)
43 Strokes with unknown onset, 10 (22%)
received IV-tPA
Perfusion–diffusion mismatch (MRI) One asymptomatic ICH, no symptomatic ICH (32)
32 Strokes with unclear onset Perfusion–diffusion mismatch and
FLAIR(non-quantitative)
No difference in frequency of symptomatic ICH
and 3 months outcome (mRS after 3 months) to
treatment within 4.5 h
(33)
430 Strokes with unknown onset, in 83 (19.3%)
of these thrombolysis (10% IV-tPA only)
Perfusion–diffusion mismatch and
FLAIR(non-quantitative)
Benefit of treatment (after 3 months: 44.6% mRS
0–2; 28.9% mRS 0–1) with safe MRI-based
indication (symptomatic ICH in 6%)
(35)
IV-tPA, intravenous tissue plasminogen activator; NECT, non-enhanced computed tomography; CT-A, CT-angiography; TCD, transcranial Doppler ultrasound; FLAIR,
fluid attenuated reversion recovery; ICH, intracranial hemorrhage.
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and efficacy of thrombolysis in wake-up stroke can only be drawn
from randomized clinical trials.
RANDOMIZED CONTROLLED CLINICAL TRIALS OF
THROMBOLYSIS IN WAKE-UP STROKE
Currently, two randomized controlled trials of intravenous throm-
bolysis allow the enrollment of patients with wake-up stroke:
WAKE-UP and EXTEND.
EXTEND (ClinicalTrials.gov. Identifier: NCT00887328) is
a randomized, multicentre, double-blinded, placebo-controlled
phase III trial of intravenous thrombolysis with rt-PA in ischemic
stroke patients (31). Treatment has to be initiated between 3 h (or
4.5 h depending on local practice) up to 9 h of symptom onset,
or in case of wake-up stroke. For wake-up stroke, the midpoint
between sleep onset (or last known to be normal) and time of
waking-up must not exceed 9 h. Further clinical inclusion crite-
ria include a National Institutes of Health Stroke Scale (NIHSS)
score of 4–26. Patients are studied by MRI including diffusion and
perfusion MRI or CT including CT-perfusion and randomized to
either treatment with placebo or Alteplase (0.6 or 0.9 mg/kg body-
weight based on local practice) if they show a penumbral pattern
on MRI or CT. Penumbral pattern is defined by infarct core volume
<70 ml, perfusion lesion/infarct core mismatch ratio >1.2, and
absolute mismatch >10 ml. For definition of the perfusion lesion
Tmax >6 s for MRI and CT is used, while infarct core is defined
using MRI diffusion imaging or CT-CBF imaging. The primary
outcome measure is a favorable outcome defined by a score of 0–1
on the mRS at day 90. EXTEND aims to enroll 400 patients in Aus-
tralia and in an accompanying study in international study sites
(EXTEND international). There is a European companion study
under preparation (ECASS 4-EXTEND-Europe), which will only
use MRI for patient enrollment.
WAKE-UP (ClinicalTrials.gov. Identifier: NCT01525290) is the
first clinical trial to use the novel approach of DWI-FLAIR-
mismatch to prospectively identify patients for thrombolysis.
WAKE-UP is an investigator-initiated, interventional, random-
ized, double-blind, placebo-controlled, parallel-assignment, inter-
national, multi-center efficacy, and safety study (56). The aim of
WAKE-UP is to test efficacy and safety of MRI-based intravenous
thrombolysis with rt-PA (Alteplase) in patients with unknown
symptom onset, e.g., patients waking-up with stroke symptoms
who otherwise fulfill the approval criteria for intravenous throm-
bolysis in acute stroke. Patients fulfilling clinical inclusion and
exclusion criteria will undergo MRI including DWI and FLAIR.
They will be randomized 1:1 to either treatment or placebo if MRI
is indicative of lesion age of less than 4.5 h, i.e., shows a DWI-
FLAIR-mismatch. Clinical inclusion criteria include age between
18 and 80 years and a disabling neurological deficit. Primary effi-
cacy endpoint is favorable outcome defined by a score of 0–1 on the
mRS 90 days after stroke. Primary safety endpoints are Mortality
and death or dependency 90 days after stroke. WAKE-UP plans to
enroll 800 patients in 40–60 study sites in six European countries
and has started recruitment in October 2012.
CONCLUSION
Patients waking-up with stroke symptoms represent a large group
of stroke patients who are currently excluded from intravenous
thrombolysis based on licensing criteria. Growing evidence from
clinical and imaging studies suggests that a relevant proportion
of patients with wake-up stroke might benefit from reperfusion
treatment and be promising candidates for intravenous thrombol-
ysis. Different imaging approaches have been suggested to select
wake-up stroke patients for thrombolysis, including multipara-
metric CT and MRI. Approaches currently under investigation
involve the identification of tissue at risk of infarction indepen-
dent from time by penumbral imaging and the identification of
patients within the approved time-window for thrombolysis by
the concept of DWI-FLAIR-mismatch. Both approaches are cur-
rently tested in large randomized controlled trials. The results of
these trials are expected to change clinical practice by making avail-
able effective and safe treatment for a large group of acute stroke
patients currently excluded from specific acute treatment.
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